Combination of Hormonal and Psychological Treatment for Female Sexual Unresponsiveness: a Comparative Study

1978 ◽  
Vol 133 (4) ◽  
pp. 339-346 ◽  
Author(s):  
Anthony Carney ◽  
John Bancroft ◽  
Andrew Mathews
Keyword(s):  
Drug Therapy ◽  
Side Effects ◽  
Comparative Study ◽  
Factorial Design ◽  
Psychological Treatment ◽  
Controlled Study ◽  
Testosterone Therapy ◽  
End Of Treatment

SummaryThirty-two couples with the presenting problem of female sexual unresponsiveness were treated in a controlled study using a balanced factorial design. Treatment involved a combination of drug therapy and counselling. Half the subjects received testosterone and half diazepam, half received weekly and half monthly counselling. They were assessed before treatment, at the end of treatment and at six months follow-up.Those receiving testosterone did significantly better on a number of behavioural and attitudinal measures than the diazepam group. There were no notable differences in outcome between the two counselling regimes. There were no undesirable side-effects with the testosterone.Further work is needed to establish the indications for testosterone therapy for unresponsive women.

Alprazolam and Exposure for Panic Disorder with Agoraphobia

1994 ◽  
Vol 164 (5) ◽  
pp. 652-659 ◽  
Author(s):  
Metin Başoglu ◽  
Isaac M. Marks ◽  
Cengiz Kiliç ◽  
Richard P. Swinson ◽  
Homa Noshirvani ◽  
...  
Keyword(s):  
Side Effects ◽  
Panic Disorder ◽  
Drug Treatment ◽  
Psychological Treatment ◽  
Illness Severity ◽  
Withdrawal Symptoms ◽  
Severe Withdrawal ◽  
End Of Treatment

Patients with panic disorder plus agoraphobia had 8 weeks of drug treatment (alprazolam or placebo) plus psychological treatment (exposure or relaxation). At the end of treatment at week 8, 40 patients who had become much/very much improved rated how much their gains were attributable to medication or to their own efforts. During the tapering-off to week 16, and treatment-free follow-up to week 43, patients who at week 8 had attributed their gains to medication and felt less confident in coping without tablets had more severe withdrawal symptoms and greater loss of gains than did patients who at week 8 had attributed their gains to their own efforts during treatment. Baseline illness severity, greater age, higher expectations from drug treatment, and more side-effects of drugs during treatment all predicted more external attributions (i.e. to the effect of drugs) but did not independently predict relapse. Patients on alprazolam compared with placebo had more drug attributions. Though drug attributions predicted relapse in both alprazolam and placebo groups, predictions were stronger in the alprazolam group.

scholarly journals A PROSPECTIVE STUDY TO ANALYSE THE SIDE EFFECTS OF OLMESARTAN MEDOXOMIL AND ENALAPRIL IN HYPERTENSIVE SUBJECTS

2018 ◽  
Vol 11 (12) ◽  
pp. 258
Author(s):  
Parminderpal Singh ◽  
Kiranjit Kiranjit
Keyword(s):  
Drug Therapy ◽  
Side Effects ◽  
Postural Hypotension ◽  
Olmesartan Medoxomil ◽  
National Commission ◽  
Group A ◽  
Group B ◽  
Taste Alteration ◽  
A Prospective Study

Objective: The present study was aimed to analyze the side effects of olmesartan medoxomil and enalapril in hypertensive subjects.Methods: The study consisted of newly diagnosed hypertension categorized according to 7th report of Joint National Commission on prevention, detection, evaluation, and treatment of high blood pressure. The subjects were divided into two groups. The Group A subjects received olmesartan, and Group B subjects received enalapril. Pressure was recorded both in supine and sitting positions. The appearance of side effects was observed in the follow-up, i.e., dry cough, headache, postural hypotension, angioedema, dizziness, skin rashes, taste alterations, and urticaria. A statistical data were prepared on the basis of information obtained and analyzed thoroughly for antihypertensive effects and side effects of olmesartan and enalapril. SPSS software was used for analysis.Results: There was observed an increase in the incidence of taste alteration with drug therapy in Group B (Enalapril). There was observed an increase in the incidence of postural hypotension with drug therapy in both groups. In Group A (Olmesartan), the incidence of postural hypotension at the beginning of trial, 4 weeks, and 8 weeks was 0%, 2%, and 2%, respectively. In Group A (Olmesartan), there was no incidence of a headache at the beginning of trial, at 4 weeks and 8 weeks.Conclusion: From the study, it can be concluded that both olmesartan and enalapril are effective in Stage I and Stage II hypertension, but olmesartan is tolerated well with lesser side effects.

scholarly journals Efficacy of acamprosate in the treatment of alcohol-dependent outpatients

2003 ◽  
Vol 25 (3) ◽  
pp. 156-159 ◽  
Author(s):  
Danilo Antonio Baltieri ◽  
Arthur Guerra de Andrade
Keyword(s):  
Side Effects ◽  
Alcohol Dependence ◽  
Placebo Treatment ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Continuous Abstinence ◽  
Icd 10 ◽  
Alcohol Dependent

OBJECTIVE: To evaluate the efficacy and security of acamprosate in the treatment of 75 men, aged 18 to 59 years, with diagnosis of alcohol dependence according to the ICD-10. METHODS: Double-blind, placebo-controlled study, 24-week long. After a one-week detoxification period, patients were randomly divided in two groups: the first group received acamprosate (six tablets of 333 mg/d for 12 weeks) and the second group received placebo (six tablets for 12 weeks). After the first 12 weeks, patients continued the follow-up for further 12 weeks without medication. RESULTS: Patients who were receiving acamprosate showed significantly higher continuous abstinence time within the 24 weeks of treatment compared with patients who were assigned to placebo treatment (p=.017). Twenty-five percent of patients who were receiving acamprosate and 20% of the placebo-treated patients dropped out. Few side-effects were reported in both groups. CONCLUSION: Acamprosate proved to be safe and effective in treating alcohol-dependent patients and to maintain the abstinence during 24 weeks.

scholarly journals Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children

2019 ◽  
Author(s):  
Arkendu Chatterjee ◽  
Sabyasachi Bandyopadhyay ◽  
Samir Kumar Bandyopadhyay
Keyword(s):  
Placebo Group ◽  
Side Effects ◽  
Cyclosporine A ◽  
Controlled Study ◽  
Vernal Keratoconjunctivitis ◽  
Indian Children ◽  
Steroid Dependent ◽  
Sparing Effect ◽  
Steroid Sparing

Purpose: To evaluate the efficacy, safety, and steroid-sparing effect of topical cyclosporine A (Cs A) 0.05% in patients with moderate to severe steroid dependent vernal keratoconjunctivitis (VKC). Methods: A prospective, comparative, placebo controlled study was carried out on 68 VKC patients, with 34 patients treated with topical Cs A 0.05% and the remaining 34 with topical carboxymethyl cellulose 0.5% (placebo). Both groups also received topical loteprednol etabonate 0.5%. Symptom (itching, photophobia, tearing, and discharge) score, sign (tarsal and limbal papillae, corneal involvement, and conjunctival hyperemia) score, and drug score (steroid drop usage/day/eye) were recorded at baseline and each followup visit. The intraocular pressure (IOP) measurement and evaluation of any ocular side effects were carried out. Results: Significant reduction in symptom score and sign score was seen in both groups. Cs A group significantly showed more reduction in symptom (P < 0.0001 in all follow-up visits) and sign (P < 0.0001 in all follow-up visits) scores compared to the placebo group. At day 7, mean steroid usage reduced from 4 to 3.44 ± 0.5 and 3.79 ± 0.4 in Cs A and placebo groups, respectively (P < 0.0001). Steroid drops completely stopped in 21 patients at day 60 in the Cs A group compared to none in the placebo group. No significant rise in IOP or any side effects were noted in either group. Conclusion: Topical Cs A 0.05% is effective and safe in patients with moderate to severe VKC with good steroid-sparing effect.

scholarly journals A Comparative Study on the Efficacy of Kantkari and Vasa Lozenges in Children with Kasa (Cough)-Study Protocol

2021 ◽  
pp. 25-33
Author(s):  
Sabir Ali ◽  
Renu Rathi ◽  
Bharat Rathi
Keyword(s):  
Comparative Study ◽  
Controlled Study ◽  
Control Group ◽  
Double Blind ◽  
Abnormal Sound ◽  
Sequence Method ◽  
Group A ◽  
Objective Outcomes ◽  
Group B

Background: Kasa is the outcome due to release of obstructed Vayu resulting in the production of abnormal sound, which may be productive or dry. Kasa is one of the primary diseases of Pranavaha srotas, and can cause disturbances in other body functions. Prevalence of cough in India is 5% to 10% while acute cases of cough is 39% and chronic cases of cough is 29% reported in Maharashtra. This research drug is taken to check its efficacy on both the types of cough, dry as well as productive with acute or chronic origin. It has a good palatability and liked by children as it appears as candy. Many studies have been carried out on Kasa with different formulations so far like vati, churna, ghrita but they have no fast and long lasting action with different level of efficacy. Many lozenges are also available in the market but no studies have been done. Objective: Comparative Study on the efficacy of Kantakari lozenges with Vasa lozenges in the clinical features of Kasa by subjective criteria such as Peenasa-(running nose), Kasa, Aruchi-(taste impliedness), kanthkandu(throat itching), kaphnishthivan (Sputum) and objective criteria as adventitious sound and AEC-absolute eosinophil count, TLC-total leucocytes count, and DLC-differential leucocyte count. Materials and Methods: The present study is designed as a Double Blind, Randomized Controlled Study in which total 60 patients will be enrolled. Patients will be randomly divided (by computer generated sequence method) in two with 30 patients in each group. In group A, Vasa lozenges and in group B Kantkari lozenges will be given for 7 days. Assessment of the patients will be done on 3rd and 7th day during study after intervention and post treatment follow up will be taken on 14th& 21st day from the enrolled date. Results: Efficacy of both the lozenges will be observed in subjective and objective outcomes. Conclusion: Kantkari lozenges (trial group) is expected to be more effective than Vasa lozenges (control group) in the management of Kasa as Vata, Kapha are more dominant in the pathology of Kasa in children and Kantakari is a good Vatakaphahar drug added with Pippali to act synergistically.

scholarly journals An open trial of individualized face-to-face cognitive behavior therapy for psychological distress in parents of children after end of treatment for childhood cancer including a cognitive behavioral conceptualization

PeerJ ◽  
2018 ◽  
Vol 6 ◽  
pp. e4570 ◽  
Author(s):  
Lisa Ljungman ◽  
Martin Cernvall ◽  
Ata Ghaderi ◽  
Gustaf Ljungman ◽  
Louise von Essen ◽  
...  
Keyword(s):  
Psychological Distress ◽  
Childhood Cancer ◽  
Psychological Treatment ◽  
Cognitive Behavioral ◽  
Depression And Anxiety ◽  
Face To Face ◽  
The Core ◽  
End Of Treatment ◽  
Post Assessment

ObjectiveA subgroup of parents of children who have been treated for childhood cancer report high levels of psychological distress. To date there is no empirically supported psychological treatment targeting cancer-related psychological distress in this population. The aim of the current study was to test the feasibility and preliminarily evaluate the effect of individualized face-to-face cognitive behavior therapy (CBT) for parents of children after the end of treatment for childhood cancer. A secondary aim was to present a cognitive behavioral conceptualization of cancer-related distress for these parents.MethodsAn open trial was conducted where 15 parents of children who had completed successful treatment for cancer three months to five years earlier and who reported psychological distress related to a child’s previous cancer disease were provided CBT at a maximum of 15 sessions. Participants were assessed at baseline, post-intervention, and three-month follow-up using self-reported psychological distress (including posttraumatic stress symptoms (PTSS), depression, and anxiety) and the diagnostic Mini-International Neuropsychiatric Interview. Feasibility outcomes relating to recruitment, data collection, and delivery of the treatment were also examined. Individual case formulations for each participant guided the intervention and these were aggregated and presented in a conceptualization detailing core symptoms and their suggested maintenance mechanisms.ResultsA total of 93% of the participants completed the treatment and all of them completed the follow-up assessment. From baseline to post-assessment, parents reported significant improvements in PTSS, depression, and anxiety with medium to large effect sizes (Cohen’sd= 0.65–0.92). Results were maintained or improved at a three-month follow-up. At baseline, seven (47%) participants fulfilled the diagnostic criteria for major depressive disorder and four (29%) fulfilled the criteria for posttraumatic stress disorder, compared to none at a post-assessment and a follow-up assessment. The resulting cognitive behavioral conceptualization suggests traumatic stress and depression as the core features of distress, and avoidance and inactivity is suggested as the core maintenance mechanisms.ConclusionThe treatment was feasible and acceptable to the participants. Significant improvements in distress were observed during the study. Overall, results suggest that the psychological treatment for parents of children after end of treatment for childhood cancer used in the current study is promising and should be tested and evaluated in future studies.

The treatment of sexually dysfunctional men without partners: A controlled study of three behavioural group approaches

1997 ◽  
Vol 170 (4) ◽  
pp. 338-344 ◽  
Author(s):  
Ariel Stravynski ◽  
Giles Gaudette ◽  
Alain Lesage ◽  
Nira Arbel ◽  
Pascale Petit ◽  
...  
Keyword(s):  
Sexual Dysfunction ◽  
Controlled Study ◽  
Meaningful Change ◽  
Treatment Groups ◽  
End Of Treatment ◽  
Interpersonal Difficulties ◽  
One Year ◽  
The One ◽  
Single Men

BackgroundModels of sex therapy for sexual dysfunction in single men are available, but their value is not well established. This controlled study compared three approaches to the treatment of sexually dysfunctional single men.MethodSixty-nine single men diagnosed as sexually dysfunctional were randomly assigned to treatments focusing on either their sexual dysfunction, their interpersonal problems, a combination of both or a waiting list; 51 completed treatment and 50 the one-year follow-up. Treatment was administered in small groups in 15 weekly sessions and four six-weekly sessions during the first six months of a year-long follow-up.ResultsNo clinically meaningful change was observed during the waiting period. In contrast, a significant and equivalent improvement was observed in all treatment groups by the end of treatment. However, differences between them were in evidence at 6 and 12 months' follow-up.ConclusionsBoth treatments paying attention to the patients' interpersonal difficulties resulted in significantly better outcomes overall than the approach that concentrated on problems in sexual functioning alone.

scholarly journals Treating winter depressive episodes in bipolar disorder: an open trial of light therapy

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Lotte J. E. van Hout ◽  
Lisette E. P. Rops ◽  
Claudia J. P. Simons
Keyword(s):  
Bipolar Disorder ◽  
Side Effects ◽  
Depressive Symptomatology ◽  
Light Therapy ◽  
Open Trial ◽  
Winter Depression ◽  
End Of Treatment ◽  
Depressive Episodes ◽  
Therapy Protocol

Abstract Background Light therapy has been used to treat winter depression in bipolar disorder, although the dose, duration, and timing of treatment have differed. The present study is an open trial of light therapy for depressive episodes in autumn/winter using a Dutch protocol specific for patients with a bipolar disorder. Methods Data were collected for the seasons September–April 2017–2018 and September–April 2018–2019. In total, 58 patients received light therapy for a minimum of 7 days and a maximum of 21 days; there was a follow-up measurement after two weeks. Outcomes were quick inventory of depressive symptomatology (QIDS) scores and side effects. Results QIDS scores were significantly lower at the last day of therapy (B = − 6.00, p < 0.001) and 2 weeks after the end of treatment (B = − 6.55, p < 0.001) compared with pre-intervention. Remission (QIDS ≤ 5) was reached in 55% of the treatments and response (50% symptom reduction) in 57% of the treatments. Side effects were mild; two hypomanic periods occurred. Conclusions The Dutch light therapy protocol for patients with a bipolar disorder may be effective in treating a seasonal depression and side effects are mild. Light therapy deserves a prominent place in the treatment because effects may be large and quick.

scholarly journals COMPARISON BETWEEN TWO INTENSE PULSED LIGHT DEVICES USED FOR PHOTOEPILATION

2019 ◽  
pp. 1-3
Author(s):  
Honório Sampaio Menezes ◽  
Roberto Chacur ◽  
Simone Merceo Bacchi Cirino ◽  
Miguel D'Avilla Sobrinho ◽  
Nívea Maria Bordin da Silva Chacur
Keyword(s):  
Patient Satisfaction ◽  
Side Effects ◽  
Intense Pulsed Light ◽  
Hair Removal ◽  
Pulsed Light ◽  
Hair Density ◽  
Patient Satisfaction Scores ◽  
End Of Treatment

Background: Unwanted hair growth is a common aesthetic problem. Intense pulsed light hair removal has emerged as a leading treatment option for long-term depilation. Material and methods: Patients with phototypes I to III (n = 800) were subjected to 4 regular sessions (n=3200) of intense pulsed light, with 2 months follow-up at the end of treatment. Two devices (Silk'n, and Rejuvene) were analyzed about adverse effects and satisfaction. Observation and results: This study of 3.200 ILP sessions did not show any serious side effects and the number of side effects was minimal (8.75% to 10.5%). Patient satisfaction was over 90%. Both devices provided a similar and signicant reduction in hair density. Conclusions: Both tested sources proved its safety and efcacy for hair removal. Patient satisfaction scores were in agreement with the treatment efcacy. The incidence of side effects has no difference between devices. Axillary bromhidrosis was an unexpected side effect.

Comparative and Non-Comparative Studies of the Efficacy and Tolerance of Tioconazole Cream 1% versus Another Imidazole and/or Placebo in Neonates and Infants with Candidal Diaper Rash and/or Impetigo

1987 ◽  
Vol 15 (1) ◽  
pp. 23-31 ◽  
Author(s):  
D. L. Gibbs ◽  
P. Kashin ◽  
S. Jevons
Keyword(s):  
Side Effects ◽  
Mycological Cure ◽  
Cure Rate ◽  
Treatment Area ◽  
Disease Symptoms ◽  
End Of Treatment ◽  
Long Term Follow Up ◽  
Neonates And Infants

Eleven open multicentre studies were conducted to evaluate the efficacy of tioconazole cream 1% as a treatment for diaper rash with or without fungal ( Candida) involvement, or impetigo in neonates and infants. In the dermal candidiasis/diaper rash group, 320 patients had either tioconazole ( n = 220), a comparative imidazole ( n = 43), or vehicle cream ( n = 57) applied to the affected area twice daily. Twenty-one impetigo patients had only tioconazole cream 1% applied three times daily to lesions. The overall cure rate (patients with both clinical and mycological cure) at the end of treatment for tioconazole treated patients was 78%, for the comparative imidazole group it was 76% and for vehicle cream it was 39%. At the long-term follow-up evaluation approximately 6 weeks after treatment for patients with diaper rash, the overall cure rate was about the same in both tioconazole- and comparative imidazole-treated patients (87% and 90%, respectively), and 14% in patients using vehicle cream. Side-effects were coincident with disease symptoms and consisted primarily of erythema localized to the treatment area; they occurred in 5.4% (13/241) of the patients who received tioconazole and in 21% (9/43) of the patients who received comparative imidazole (econazole or miconazole). No side-effects were reported in this open study for the 57 patients who used vehicle cream. The results of these studies show that tioconazole cream 1% is safe and effective for the treatment of neonates and infants with dermal candidiasis, diaper rash and impetigo.

Sign in / Sign up

Export Citation Format

Share Document